Multiple Sclerosis & Immune Disorders

Filter Your Results

 

News

 

Shared Decision-Making in Multiple Sclerosis Management

Amy Perrin Ross, APN, MSN, CNRN, MSCN

April 2017—Engaging and informing patients about the disease, therapy, and lifestyle is the cornerstone of effective multiple sclerosis care.

New Evidence Suggests Shared Genetic Origin of ALS and Schizophrenia

April 2017—Exercise Shown to Improve Cognitive Impairment After Stroke New research presented at the International Stroke Conference 2017 in February suggests that structured exercise…

Ocrevus Receives FDA Greenlight for Relapsing, Primary Progressive Forms of Multiple Sclerosis

Tuesday, March 28, 2017—The FDA has approved Ocrevus (ocrelizumab, Roche/Genentech) for the treatment of both relapsing and primary progressive forms of multiple sclerosis. Ocrelizumab is a…

FDA Accepts NDA Filing for MT Pharma’s Investigational ALS Treatment

Friday, February 17, 2017—The FDA accepted the Mitsubishi Tanabe Pharma’s New Drug Application (NDA) for edaravone (MCI-186), an intravenous treatment for amyotrophic lateral sclerosis (ALS). Eda…

New Corticosteroid Approved for Duchenne Muscular Dystrophy

Friday, February 10, 2017—The FDA approved Emflaza (deflazacort) tablets and oral suspension to treat patients age five years and older with Duchenne muscular dystrophy (DMD). Emflaza is the first FDA …

Blood Biomarker for Quick and Accurate Prognosis of MS Identified

Tuesday, February 07, 2017—A newly discovered blood biomarker may aid physicians in identifying the type of multiple sclerosis (MS) in their patients. In a study recently published in Scientific Reports…

Newly Published Phase 3 Data Boost Efficacy Profile of Ocrevus in Primary Progressive and Relapsing MS

Wednesday, January 04, 2017—As the FDA continues its review of the Biologics License Application (BLA) for Genentech’s Ocrevus (ocrelizumab), key phase 3 findings reviewing the agent’s safety…

FDA Extends Review of MS Agent Ocrevus to March 2017

Wednesday, December 21, 2016—The FDA has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics License Application of Genentech’s investigational agent for the tre…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in January 2002, Practical Neurology strives to enhance quality of care and improve the daily operation of neurology practices. Each month, our experts explain the real-world significance of recent advances in neurologic science and offer step-by-step advice on how to overcome the clinical and business challenges neurologists face. Our straightforward, how-to articles give neurologists tools they can put into practice right away.

 
  • BRYN MAWR COMMUNICATIONS III, LLC